STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Amesite Announces NurseMagic™ Sales Growth for Hospice Care Team with Documentation Solution to Ensure Reimbursements, Reduce Audit Risk for Owners

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Amesite (NASDAQ: AMST) announced significant growth in its NurseMagic™ hospice documentation tool adoption. The AI-driven solution addresses critical documentation challenges for hospice care providers, ensuring proper reimbursements and reducing audit risks.

Key highlights include:

  • Deal sizes with hospice providers grew by nearly 1,000% over the last three months
  • NurseMagic™ sales increased by over 3,000% in the same period
  • The platform now supports entire care teams including nurses, clinical professionals, and non-clinical staff
  • Specialized hospice notes feature focuses on capturing patient decline documentation

The expansion comes as the hospice care market, currently valued at $31.21 billion, is projected to reach $39.09 billion by 2030 with a 4.61% CAGR. End-of-life care represents 21% of lifetime healthcare costs, making efficient documentation important for market growth.

Loading...
Loading translation...

Positive

  • NurseMagic™ sales growth of 3,000% in 3 months
  • Deal sizes with hospice providers up 1,000%
  • Expansion to support entire care teams
  • Operating in growing market projected to reach $39.09B by 2030
  • Successful launch of automated enterprise sales flow

Negative

  • None.

Insights

Amesite's announcement showcases impressive sales growth for its NurseMagic™ AI documentation platform in the hospice care segment. The reported 3,000% growth in sales and 1,000% increase in deal sizes over just three months signal strong market traction. While absolute revenue figures aren't disclosed, these growth metrics indicate significant momentum as the company shifts to enterprise sales.

What's particularly compelling is Amesite's solution addresses a direct revenue pain point for hospice providers - ensuring proper documentation of patient decline to secure reimbursements. By focusing on this critical documentation challenge, Amesite has positioned its AI platform as a solution that directly impacts customers' bottom line, creating a clear value proposition that's driving adoption.

The hospice care market represents a strategic growth opportunity, projected to expand from $31.21 billion to $39.09 billion by 2030 (CAGR 4.61%). With end-of-life care comprising 21% of lifetime healthcare costs, proper documentation for reimbursement is increasingly critical for providers.

Amesite's expansion from selling to individual nurses to entire care teams, including non-clinical staff, demonstrates a successful land-and-expand strategy. The transition to web-based enterprise sales appears to be accelerating deal closure and enabling the company to target larger organizations, which should provide more sustainable revenue streams if customer retention remains strong.

Amesite's announcement of 3,000% sales growth and 1,000% larger deal sizes for NurseMagic™ over just three months demonstrates exceptional traction in the hospice documentation market. While the absolute revenue base isn't disclosed, these growth rates suggest the company has found product-market fit in a critical healthcare niche with substantial revenue potential.

The company's AI solution addresses documentation challenges that directly impact healthcare providers' revenue through reimbursements. This value proposition creates a compelling ROI case for customers, as proper documentation directly translates to captured revenue that would otherwise be lost. This clear financial benefit should support continued sales momentum and potentially higher pricing power.

Strategically, Amesite's expansion to serve entire care teams rather than just individual nurses represents an effective account expansion strategy. By covering the full care continuum within hospice organizations, they're increasing their addressable market and revenue per customer while creating higher switching costs. The shift to enterprise sales targeting larger organizations should improve sales efficiency and potentially lead to more predictable revenue streams.

The hospice market's projected growth to $39.09 billion by 2030 provides a substantial expansion runway. With end-of-life care representing 21% of lifetime healthcare spending, Amesite is positioning itself in a critical and growing segment of healthcare technology that directly impacts providers' financial performance, creating a strong foundation for continued growth.

Amesite's Hospice Documentation Addresses Key Pain in Market: Losses in Reimbursements Due to Deficient Documentation

DETROIT, March 05, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, today announced the successful adoption of its hospice documentation tool in NurseMagic™. Hospice Notes in NurseMagic™ now solves the major pain for hospice agencies, organizations and conglomerates: proper documentation of patient decline. Missing documentation means unreimbursed charges – but this risk can be eliminated with use of NurseMagic™’s AI, which assists care providers in assuring fast, accurate documentation.

Amesite reports that over the last three months, deal sizes with hospice providers have grown by nearly 1,000%. Additionally, Amesite is now winning entire workforces, with the rollout of a tool specifically designed for frontline staff, including CNAs, nurse aides and caregivers. With the rollout of web-based enterprise sales, Amesite has reported that its sales team is closing deals faster, and now, winning larger deals.

Brandon Owens, VP of Sales at Amesite, said, “Hospice care is a vital and rapidly growing segment for NurseMagic™. We now support entire care teams—including nurses, other clinical professionals, and key non-clinical staff such as social workers and nurse aides. NurseMagic™ sales have grown by over 3,000% over the last three months, when we began ramping enterprise sales nationally. We expect that both deals and deal sizes will continue to grow in B2B as we focus on sales with larger organizations.”

Sai Nittala, Senior AI Manager at Amesite, said, “We specifically tuned our models to serve the hospice sector with specialized hospice notes, that focus on capturing patient decline. This function is essential for proper documentation and reimbursements, and our customers tell us that this level of detail not only improves compliance but also saves administrative workload, allowing staff to focus on client care.”

Amesite CEO Dr. Ann Marie Sastry said, “Amesite continues to expand our footprint across healthcare with NurseMagic™ into the fast-growing segments that enable the U.S. healthcare system to become more efficient. We entered the market for nurses in three segments, and we continue to rollout capabilities to win more segments, using data from the industry’s largest group of professionals – nurses – to inform and improve our technology, reach and sales.”

End of life care presently comprises 21%1,2 of a person’s lifetime healthcare cost. Hospice care benefits patients, family members, and caregivers with increased satisfaction and quality of life, improved pain control, and reduced physical and emotional distress while simultaneously reducing costs over standard care, making hospice care an important factor in improving overall healthcare efficiency.

Rapid consumer acceptance and demand for hospice care has resulted in a 4.61% CAGR in the segment, which is now $31.21 billion and expected to grow to $39.09 billion by 2030, making improved documentation a major need for growth3.

Rollout of the expanded hospice capability follows Amesite’s successful launches of Automated Enterprise Sales Flow, Enterprise Sales to Large Franchisees and Paid Consumer Subscriptions as Amesite continues to expand its reach both vertically and horizontally across healthcare.

About Amesite Inc.

Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the $330 billion home and healthcare segments. Its flagship product, NurseMagic™, streamlines documentation for nurses and caregivers, reducing the time required from 20 minutes to just 20 seconds. NurseMagic™ is used by over 100 professions, improved care, enhanced operational efficiency and improved financial performance. Built on proprietary AI trained on industry-specific data, NurseMagic meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages.

Forward-Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
ir@amesite.com

Sources

  1. https://www.debt.org/medical/hospice-costs/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC1361028/
  3. https://www.grandviewresearch.com/industry-analysis/us-hospice-market

FAQ

How much has Amesite's NurseMagic™ sales grown in hospice care over the last 3 months?

NurseMagic™ sales have grown by over 3,000% in the last three months since beginning national enterprise sales.

What is the main problem that AMST's NurseMagic™ solves for hospice providers?

NurseMagic™ solves the problem of proper documentation of patient decline, preventing unreimbursed charges through AI-assisted documentation.

What is the projected market size for hospice care by 2030 according to AMST's release?

The hospice care market is expected to grow from $31.21 billion to $39.09 billion by 2030, with a 4.61% CAGR.

What percentage of lifetime healthcare costs is spent on end-of-life care according to AMST?

End-of-life care comprises 21% of a person's lifetime healthcare costs.

How much have AMST's deal sizes with hospice providers increased recently?

Deal sizes with hospice providers have grown by nearly 1,000% over the last three months.
Amesite Inc

NASDAQ:AMST

AMST Rankings

AMST Latest News

AMST Latest SEC Filings

AMST Stock Data

10.52M
3.23M
23.89%
8.59%
1.24%
Software - Application
Services-prepackaged Software
Link
United States
ANN ARBOR